TG6050 is an oncolytic virus derived from Transgene’s Invir.IO® platform encoding interleukin-12 (IL-12) and an anti-CTLA4 antibody, with the potential to trigger a powerful antitumor immune response.
The Phase I Delivir trial will evaluate the intravenous (IV) administration of this novel multi-armed immunotherapy in patients with recurrent metastatic advanced non-small cell lung cancer.
Intravenous administration extends the use of oncolytic viruses to a much wider range of solid tumors compared to intratumoral administration, broadening TG6050’s potential addressable markets.
Strasbourg, France, May 10, 2023, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the first patient has been dosed in Delivir, a Phase I clinical trial evaluating TG6050. This multi-mechanism oncolytic immunotherapy is administered intravenously in patients with recurrent metastatic advanced non-small cell lung cancer (NSCLC).
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer